

Stelara[®] Prior Authorization Request Form (Page 1 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)			
Member Name:			Provider Name:			
Insurance ID#:			NPI#: Specialty:			
Date of Birth:			Office Phone:			
Street Address:			Office Fax:			
City:	State:	Zip:	Office Street Address:			
Phone:			City: State:			Zip:
Medication Information (required)						
Medication Name:			Strength:	gth: Dosage Form:		
Check if requesting brand			Directions for Use:			
Check if request is for continuation of therapy						
Clinical Information (required)						
Select the diagnosis below: Active psoriatic arthritis (PsA) Moderate to severe chronic plaque psoriasis Moderately to severely active Crohn's disease Moderately to severely active ulcerative colitis Other diagnosis:						
Clinical information: Select if the requested medication is prescribed by or in consultation with one of the following specialists: Dermatologist Gastroenterologist Rheumatologist Other Will the requested medication be used in combination with another biologic agent? Yes No						
For active psoriatic arthritis (PsA), also answer the following: Has the patient had an inadequate response to, intolerance to, or contraindication to methotrexate? U Yes UNo						
For moderate to severe chronic plaque psoriasis, also answer the following: Has the patient had an inadequate response to, intolerance to, or contraindication to conventional therapy with at least one of the following: phototherapy or one or more oral systemic treatments (i.e., methotrexate, calcipotriene, cyclosporine, acitretin, sulfasalazine, tazarotene, corticosteroid)? Yes No List						
For moderately to severely active Crohn's disease, also answer the following: Has the patient had an inadequate response to, intolerance to, or contraindication to one or conventional therapy (e.g., azathioprine, mercaptopurine, methotrexate, corticosteroids)? Use No List						
For moderately to severely active Ulcerative Colitis, also answer the following: Has the patient had an inadequate response to, intolerance to, or contraindication to one or more conventional therapy (e.g., corticosteroids, mesalamine, balsalazide, olsalazine, azathioprine, mercaptopurine, methotrexate)? Yes No List						
Quantity limit requests: What is the quantity requested per TREATMENT? syringe every weeks What is the reason for exceeding the plan limitations? I Titration or loading dose purposes Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime) Requested strength/dose is not commercially available Other:						

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Stelara_SouthDakotaMedicaid_2024January



Stelara[®] Prior Authorization Request Form (Page 2 of 2) DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received. For urgent or expedited requests please call 1-855-401-4262. This form may be used for non-urgent requests and faxed to 1-844-403-1029.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately. Office use only: Stelara SouthDakotaMedicaid 2024January